{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:00Z","timestamp":1789419240949,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Samsung Bioepis Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejca.2019.07.015","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T19:36:08Z","timestamp":1566416168000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2\u2013positive breast cancer"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-5013","authenticated-orcid":false,"given":"Xavier","family":"Pivot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-2471","authenticated-orcid":false,"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Chan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.07.015_bib1","series-title":"Full prescribing information, Merck Sharp & Dohme Corp.","year":"2019"},{"key":"10.1016\/j.ejca.2019.07.015_bib2","series-title":"Summary of product characteristics","year":"2018"},{"key":"10.1016\/j.ejca.2019.07.015_bib3","series-title":"Herceptin (trastuzumab) powder for injection","year":"2018"},{"key":"10.1016\/j.ejca.2019.07.015_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2017.74.0126","volume":"36","author":"Pivot","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2018.01.072","article-title":"A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results","volume":"93","author":"Pivot","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.07.015_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/19420862.2017.1305530","article-title":"Drifts in ADCC-related quality attributes of Herceptin\u00ae: impact on development of a trastuzumab biosimilar","volume":"9","author":"Kim","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejca.2019.07.015_bib7","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib9","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"Buzdar","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.03.087","article-title":"HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up","volume":"62","author":"Jackisch","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.07.015_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.07.015_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.07.015_bib16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(18)30002-0","article-title":"A new era for treatment development in HER2-positive breast cancer","volume":"19","author":"Pivot","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib19","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"23","author":"Collins","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib20","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1535-7163.MCT-06-0766","article-title":"Trastuzumab causes antibody-dependent cellular cytotoxicity\u2013mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance","volume":"6","author":"Barok","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.07.015_bib21","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.015_bib22","first-page":"7","article-title":"Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy","volume":"1","author":"Zahavi","year":"2018","journal-title":"Antib Ther"},{"key":"10.1016\/j.ejca.2019.07.015_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2019.07.015_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in\u00a0vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.07.015_bib25","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-09-3704","article-title":"Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer","volume":"70","author":"Junttila","year":"2010","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:44Z","timestamp":1760732684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491930423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":25,"alternative-id":["S095980491930423X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.07.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2\u2013positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}